Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
David FV Lewis & Yuko Ito. (2010) Human CYPs involved in drug metabolism: structures, substrates and binding affinities. Expert Opinion on Drug Metabolism & Toxicology 6:6, pages 661-674.
Read now
Read now
Alan Boobis, Jean-Baptiste Watelet, Rhys Whomsley, Margherita Strolin Benedetti, Pascal Demoly & Keith Tipton. (2009) Drug interactions. Drug Metabolism Reviews 41:3, pages 486-527.
Read now
Read now
Eva Stjernschantz, Nico PE Vermeulen & Chris Oostenbrink. (2008) Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450. Expert Opinion on Drug Metabolism & Toxicology 4:5, pages 513-527.
Read now
Read now
Articles from other publishers (22)
Tyler C. Beck, Kyle R. Beck, Jordan Morningstar, Menny M. Benjamin & Russell A. Norris. (2021) Descriptors of Cytochrome Inhibitors and Useful Machine Learning Based Methods for the Design of Safer Drugs. Pharmaceuticals 14:5, pages 472.
Crossref
Crossref
Andy Pike, Beth Williamson, Stephanie Harlfinger, Scott Martin & Dermot F. McGinnity. (2020) Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discovery Today 25:10, pages 1793-1800.
Crossref
Crossref
Hanoy K. Al-Amood, Hanan F. Al-Shamsi & Hayat H. Abbas. Quantitative structure-activity relationships of some new beta amino-carbonyl compounds. Quantitative structure-activity relationships of some new beta amino-carbonyl compounds.
Liyu Zhao, Nannan Sun, Linfeng Tian, Shizhen Zhao, Bin Sun, Yin Sun & Dongmei Zhao. (2019) Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research. Bioorganic & Medicinal Chemistry Letters 29:16, pages 2016-2024.
Crossref
Crossref
Yusra Sajid Kiani & Ishrat Jabeen. (2019) Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models. Computation 7:2, pages 26.
Crossref
Crossref
Tomasz Chmiel, Anna Mieszkowska, Dagmara Kempińska-Kupczyk, Agata Kot-Wasik, Jacek Namieśnik & Zofia Mazerska. (2019) The impact of lipophilicity on environmental processes, drug delivery and bioavailability of food components. Microchemical Journal 146, pages 393-406.
Crossref
Crossref
Maryam Foroozesh, Jayalakshmi Sridhar, Navneet Goyal & Jiawang Liu. (2019) Coumarins and P450s, Studies Reported to-Date. Molecules 24:8, pages 1620.
Crossref
Crossref
Jayalakshmi Sridhar, Navneet Goyal, Jiawang Liu & Maryam Foroozesh. (2017) Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date. Molecules 22:7, pages 1143.
Crossref
Crossref
Lili Wang, Yue Hai, Lijun An, Junxiu Chen, Rongjia Liang & Xin He. (2017) Rapid screening the potential mechanism-based inhibitors of CYP3A4 from Tripterygium wilfordi based on computer approaches combined with in vitro bioassay. Bioorganic & Medicinal Chemistry 25:10, pages 2689-2700.
Crossref
Crossref
Yufeng J. Tseng, Bo-Han Su, Ming-Tsung Hsu & Olivia A. Lin. 2016. Frontiers in Molecular Design and Chemical Information Science - Herman Skolnik Award Symposium 2015: Jürgen Bajorath. Frontiers in Molecular Design and Chemical Information Science - Herman Skolnik Award Symposium 2015: Jürgen Bajorath
283
329
.
Loai Basheer, Keren Schultz, Merav Fichman & Zohar Kerem. (2015) Use of In Vitro and Predictive In Silico Models to Study the Inhibition of Cytochrome P4503A by Stilbenes. PLOS ONE 10:10, pages e0141061.
Crossref
Crossref
Bo-Han Su, Yi-shu Tu, Chieh Lin, Chi-Yu Shao, Olivia A. Lin & Yufeng J. Tseng. (2015) Rule-Based Prediction Models of Cytochrome P450 Inhibition. Journal of Chemical Information and Modeling 55:7, pages 1426-1434.
Crossref
Crossref
Syed Subhani & Kaiser Jamil. (2015) Molecular docking of chemotherapeutic agents to CYP3A4 in non-small cell lung cancer. Biomedicine & Pharmacotherapy 73, pages 65-74.
Crossref
Crossref
Loai Basheer & Zohar Kerem. (2015) Interactions between CYP3A4 and Dietary Polyphenols. Oxidative Medicine and Cellular Longevity 2015, pages 1-15.
Crossref
Crossref
Robert J. Young. 2015. Tactics in Contemporary Drug Design. Tactics in Contemporary Drug Design
1
68
.
P Beswick & A Naylor. 2013. Drug Discovery and Development. Drug Discovery and Development
119
134
.
Jayalakshmi Sridhar, Jiawang Liu, Maryam Foroozesh & Cheryl L. Klein Stevens. (2012) Insights on Cytochrome P450 Enzymes and Inhibitors Obtained Through QSAR Studies. Molecules 17:8, pages 9283-9305.
Crossref
Crossref
Robert J. Young, Darren V.S. Green, Christopher N. Luscombe & Alan P. Hill. (2011) Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. Drug Discovery Today 16:17-18, pages 822-830.
Crossref
Crossref
Chad L. Stoner, Michael R. Wester & Benjamin J. Burke. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
151
168
.
Igor Shamovsky, Chris de Graaf, Lisa Alderin, Malena Bengtsson, Håkan Bladh, Lena Börjesson, Stephen ConnollyHazel J. DykeMarco van den HeuvelHenrik Johansson, Bo-Göran Josefsson, Anna Kristoffersson, Tero Linnanen, Annea Lisius, Roope MännikköBo Nordén, Steve PriceLena Ripa, Didier Rognan, Alexander Rosendahl, Marco Skrinjar & Klaus Urbahns. (2009) Increasing Selectivity of CC Chemokine Receptor 8 Antagonists by Engineering Nondesolvation Related Interactions with the Intended and Off-Target Binding Sites. Journal of Medicinal Chemistry 52:23, pages 7706-7723.
Crossref
Crossref
Marie M. Ahlström & Ismael Zamora. (2008) Characterization of Type II Ligands in CYP2C9 and CYP3A4. Journal of Medicinal Chemistry 51:6, pages 1755-1763.
Crossref
Crossref
Mariano A.E. Pinto-Bazurco Mendieta, Matthias Negri, Carsten Jagusch, Ulrike E. Hille, Ursula Müller-Vieira, Dirk Schmidt, Klaus Hansen & Rolf W. Hartmann. (2008) Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17. Bioorganic & Medicinal Chemistry Letters 18:1, pages 267-273.
Crossref
Crossref